129 related articles for article (PubMed ID: 34845378)
1. Elevated expression of RIT1 hyperactivates RAS/MAPK signal and sensitizes hepatocellular carcinoma to combined treatment with sorafenib and AKT inhibitor.
Sun L; Xi S; Zhou Z; Zhang F; Hu P; Cui Y; Wu S; Wang Y; Wu S; Wang Y; Du Y; Zheng J; Yang H; Chen M; Yan Q; Yu D; Shi C; Zhang Y; Xie D; Guan XY; Li Y
Oncogene; 2022 Jan; 41(5):732-744. PubMed ID: 34845378
[TBL] [Abstract][Full Text] [Related]
2. HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib.
Song Z; Liu T; Chen J; Ge C; Zhao F; Zhu M; Chen T; Cui Y; Tian H; Yao M; Li J; Li H
Cancer Lett; 2019 Sep; 460():96-107. PubMed ID: 31247273
[TBL] [Abstract][Full Text] [Related]
3. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
4. [Amplification of RIT1 in hepatocellular carcinoma and its clinical significance].
Li JT; Liu W; Kuang ZH; Chen HK; Li DJ; Feng QS; Liu QC; Hu B
Ai Zheng; 2003 Jul; 22(7):695-9. PubMed ID: 12866958
[TBL] [Abstract][Full Text] [Related]
5. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
6. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
Kim MN; Lee SM; Kim JS; Hwang SG
Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
[TBL] [Abstract][Full Text] [Related]
7. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
8. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
9. [Mutation and amplification of RIT1 gene in hepatocellular carcinoma].
Li JT; Liu W; Kuang ZH; Zhang RH; Chen HK; Feng QS
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Feb; 21(1):43-6. PubMed ID: 14767908
[TBL] [Abstract][Full Text] [Related]
10. RIT1 Promotes Glioma Proliferation and Invasion via the AKT/ERK/NF-ĸB Signaling Pathway.
Che M; Lan Q
J Mol Neurosci; 2022 Aug; 72(8):1547-1556. PubMed ID: 35290620
[TBL] [Abstract][Full Text] [Related]
11. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
Newell P; Toffanin S; Villanueva A; Chiang DY; Minguez B; Cabellos L; Savic R; Hoshida Y; Lim KH; Melgar-Lesmes P; Yea S; Peix J; Deniz K; Fiel MI; Thung S; Alsinet C; Tovar V; Mazzaferro V; Bruix J; Roayaie S; Schwartz M; Friedman SL; Llovet JM
J Hepatol; 2009 Oct; 51(4):725-33. PubMed ID: 19665249
[TBL] [Abstract][Full Text] [Related]
12. BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway.
Li A; Zhang R; Zhang Y; Liu X; Wang R; Liu J; Liu X; Xie Y; Cao W; Xu R; Ma Y; Cai W; Wu B; Cai S; Tang X
Am J Transl Res; 2019; 11(9):5573-5585. PubMed ID: 31632530
[TBL] [Abstract][Full Text] [Related]
13. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
Frau M; Feo F; Pascale RM
J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
[TBL] [Abstract][Full Text] [Related]
14. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
Dietrich P; Koch A; Fritz V; Hartmann A; Bosserhoff AK; Hellerbrand C
Gut; 2018 Jul; 67(7):1328-1341. PubMed ID: 29275358
[TBL] [Abstract][Full Text] [Related]
15. Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer.
Wang C; Cigliano A; Delogu S; Armbruster J; Dombrowski F; Evert M; Chen X; Calvisi DF
Cell Cycle; 2013 Jul; 12(13):1999-2010. PubMed ID: 23759595
[TBL] [Abstract][Full Text] [Related]
16. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
[TBL] [Abstract][Full Text] [Related]
17. RIT1 suppresses esophageal squamous cell carcinoma growth and metastasis and predicts good prognosis.
Feng YF; Lei YY; Lu JB; Xi SY; Zhang Y; Huang QT; Wu QL; Wang F
Cell Death Dis; 2018 Oct; 9(11):1085. PubMed ID: 30348939
[TBL] [Abstract][Full Text] [Related]
18. RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome-associated cardiac hypertrophy.
Cuevas-Navarro A; Wagner M; Van R; Swain M; Mo S; Columbus J; Allison MR; Cheng A; Messing S; Turbyville TJ; Simanshu DK; Sale MJ; McCormick F; Stephen AG; Castel P
Sci Adv; 2023 Jul; 9(28):eadf4766. PubMed ID: 37450595
[TBL] [Abstract][Full Text] [Related]
19. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome.
Aoki Y; Niihori T; Banjo T; Okamoto N; Mizuno S; Kurosawa K; Ogata T; Takada F; Yano M; Ando T; Hoshika T; Barnett C; Ohashi H; Kawame H; Hasegawa T; Okutani T; Nagashima T; Hasegawa S; Funayama R; Nagashima T; Nakayama K; Inoue S; Watanabe Y; Ogura T; Matsubara Y
Am J Hum Genet; 2013 Jul; 93(1):173-80. PubMed ID: 23791108
[TBL] [Abstract][Full Text] [Related]
20. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice.
Wang C; Cigliano A; Jiang L; Li X; Fan B; Pilo MG; Liu Y; Gui B; Sini M; Smith JW; Dombrowski F; Calvisi DF; Evert M; Chen X
Hepatology; 2015 Jan; 61(1):200-13. PubMed ID: 25145583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]